JAK Inhibitors in 2019



Role in the therapeutic strategy in 2019

 • RA: 2nd line after failure of conventional DMARDs 

 • PsoArth: after failure of NSAID, cDMARDs and/or biologics

 • Ulcerative colitis: 3rd line after failure of 5-ASA, GCs, cDMARDS and anti-TNF-apha



Efficacy (Rheumatoid Arthritis, Psoriatic Arthritis)

 • Superior to methotrexate

 • Noninferior to combination of methotrexate + anti-TNFapha

 • Efficacy as early as 3 weeks

 • Maximum efficacy at 3 mo.



By Romain Muller via Dr. Benjamin Terrier @TerrierBen



#JAKInhibitors #Indications #Rheumatology #Management